Quick Facts

• Main Use: Treatment of relapsing forms of multiple sclerosis (MS).
• Specific Forms Treated: Clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
• Therapeutic Benefit: Helps slow the progression of disability and reduces the frequency of symptom flare-ups (relapses).

---

Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This includes patients with clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS). Its primary therapeutic benefit is to slow the rate of disability worsening and reduce the annualized relapse rate.

Administration of this medication is associated with a reduction in new or enlarging inflammatory lesions observed on MRI scans, which signifies a decrease in disease activity. For patients with active secondary progressive MS, a key benefit is the delay in sustained disability progression compared to placebo. It serves as a disease-modifying therapy to help manage the course of the condition by modulating the immune response.

Eligibility for Mayzent (Siponimod)

Mayzent is officially approved for use in adults (18 years and older) with relapsing forms of multiple sclerosis. The regulatory profile clearly defines populations who must not use the medicine (contraindications) and those requiring restricted use.

---

Absolute Contraindications

Mayzent is contraindicated in patients with the CYP2C93/3 genotype (poor metabolizers) and in individuals with severe liver impairment (Child-Pugh class C). It must not be used by patients who have experienced certain recent cardiovascular events (e.g., myocardial infarction or stroke in the last six months) or who have specific pre-existing heart conduction abnormalities (e.g., Mobitz Type II or Third-degree AV block), unless a functioning pacemaker is present. It is also contraindicated in pregnancy.

---

Population Restrictions

Safety and efficacy have not been established in children and adolescents (under 18 years). Use in patients aged 65 years and above is advised with caution due to insufficient data. Women of childbearing potential must use effective contraception during therapy and for ten days after stopping treatment. Patients with certain CYP2C9 genotypes (1/3 or 2/3) are eligible but require a reduced maintenance dose.

Interactions with other medicines and products

Mayzent (Siponimod) has officially documented interaction patterns that primarily concern its metabolic clearance and pharmacodynamic effects, based on regulatory prescribing information.

Pharmacokinetic and Metabolic Restrictions

Siponimod is primarily metabolized by the CYP2C9 and CYP3A4 enzyme systems. The co-administration of moderate CYP2C9 inhibitors or moderate or strong CYP3A4 inhibitors is not recommended due to the expectation of a significant increase in systemic exposure. Conversely, strong inducers of these enzymes are also not recommended as they may cause a significant decrease in exposure.

Critically, the use of Siponimod is contraindicated in patients with the CYP2C93/3 genotype, as this condition results in severely impaired clearance and substantially elevated plasma concentrations. Patients with intermediate metabolizing genotypes (e.g., 1/3 or 2/3) require official dose adjustments due to increased exposure.

Pharmacodynamic and Timing Constraints

Caution is required when co-administering Siponimod with drugs that decrease heart rate (such as certain beta-blockers) due to the potential for additive bradyarrhythmia and atrioventricular (AV) conduction delays. In addition, live-attenuated vaccines must be avoided during treatment and for 4 weeks after discontinuation due to the risk of additive immune system effects and vaccine ineffectiveness. Food intake delays absorption but does not affect the drug’s overall systemic exposure.

Molecular Targeting: Sphingosine 1-Phosphate Receptor Modulation

Mayzent (siponimod) is a selective sphingosine 1-phosphate (S1P) receptor modulator that specifically targets the S1P1 and S1P5 receptors. The drug's active metabolite acts as a functional agonist on these receptors, causing the S1P1 receptors on the cell surface to be rapidly removed and degraded (down-regulated). This molecular action is the first step in the cascade that restricts the mobilization of immune cells.

Peripheral Action: Lymphocyte Sequestration

The functional removal of S1P1 receptors on immune cells, primarily T and B lymphocytes, blocks the chemical signal required for them to leave the secondary lymphoid organs (like lymph nodes) and enter the bloodstream. This process effectively traps the lymphocytes in the lymph nodes, leading to a significant and sustained reduction in their concentration in the peripheral blood circulation. This physiological change results in fewer lymphocytes available in the peripheral blood to cross into target compartments.

Central Action: CNS Cell Modulation

The active drug also crosses the blood-brain barrier to work directly within the central nervous system (CNS) by binding to S1P1 and S1P5 receptors found on resident brain cells, such as glia and oligodendrocyte precursor cells (OPCs). This direct interaction modulates signaling on resident CNS cells and may influence pathways associated with cellular function and structural integrity.

Administration Route and Standard Use

Mayzent (siponimod) is administered via the oral route as a film-coated tablet and is taken once daily. The tablets must be swallowed whole with water and must not be split, crushed, or chewed. The medication can be taken with or without food.

---

Dosing and Titration Protocol

The required daily dose is determined by the patient's CYP2C9 genotype, a specific genetic marker, which must be tested prior to treatment initiation.

The standard maintenance doses are:

• 2 mg Once Daily: Recommended for patients with specific CYP2C9 genotypes (ast 1/ast 1, ast 1/ast 2, or ast 2/ast 2), beginning on Day 6.
• 1 mg Once Daily: Required for patients with reduced metabolism genotypes (ast 1/ast 3 or ast 2/ast 3), beginning on Day 5.

Treatment must be initiated with a mandatory dose escalation (titration) period, which lasts 4 or 5 days depending on the determined maintenance dose. This structured phase gradually introduces the dose.

---

Rules for Missed Doses and Specific Populations

If the maintenance treatment is interrupted for four or more consecutive daily doses, the medication must be re-initiated with the full initial titration regimen. For the pediatric population (aged 0 to 18 years), the safety and efficacy of siponimod have not been established, and therefore, no dosing recommendations are available. No dose adjustment is required for patients with renal impairment or those with mild or moderate hepatic impairment.

Research Evidence and Study Overview for Mayzent (Siponimod)

---

Evidence for Use in Active Secondary Progressive Multiple Sclerosis (SPMS)

The primary research for Siponimod in adults with active Secondary Progressive Multiple Sclerosis comes from a large, controlled study known as a Phase 3 randomized, double-blind, placebo-controlled trial. Researchers examined patients over an intermediate period, with a median follow-up of up to two years. The research primarily studied whether there were patterns related to the time to Confirmed Disability Progression (CDP), as measured on the functional scale. Findings described patterns observed in the time to disability progression that were observed in the study populations. Studies report how symptoms evolved and described patterns in the measured outcomes related to inflammatory lesion counts.

Evidence suggests that measurements of disability progression for patients with SPMS who have non-active disease—meaning those who have not had recent relapses or inflammatory lesions—remain less characterized by the existing evidence. Research has explored outcomes related to disability worsening, but the results apply only to the specific populations studied, primarily those with active disease.

---

Evidence for Use in Other Relapsing Forms of MS (RRMS and CIS)

Research supporting the broader indication for other relapsing forms of Multiple Sclerosis involves earlier, smaller trials. These studies examined outcomes related to inflammatory biomarkers and episodic symptom activity over shorter periods. Researchers studied primary measurements such as MRI lesion activity and Annualized Relapse Rate (ARR). These studies reported how symptoms evolved by describing patterns in the number of inflammatory lesions and annualized relapse rates. Evidence is limited in this population by the lack of a dedicated, large-scale Phase 3 trial focused specifically on long-term physical function.

---

Key Evidence Gaps and Areas for Future Research

Research is ongoing to fully characterize the long-term patterns related to this medicine. The main research limitation frames include the fact that the follow-up durations were limited in the initial controlled trials. The evidence highlights that data for certain groups, such as the non-active SPMS patients, remain insufficient regarding disability progression outcomes. The findings describe group patterns, but research does not provide individual predictions or determine whether an individual will respond similarly. Furthermore, research exploring the use of the medicine during pregnancy or breastfeeding is typically insufficient, where certainty remains low.

Key Studies & References

1. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

Common questions about Mayzent (FAQ)

Q: Is Mayzent meant to be a long-term medication?

Mayzent is classified as a Disease Modifying Drug (DMD) and is intended for the long-term management of chronic conditions, specifically relapsing forms of multiple sclerosis in adults.

Q: Why does Mayzent require heart monitoring when a person first starts taking it?

The required initial monitoring is due to the potential for a transient decrease in heart rate and possible conduction delays that occur when treatment begins. These cardiac effects are typically most pronounced during the first days of treatment. The initial dose escalation period is associated with gradually increasing the drug level to manage this transient effect.

Q: What kind of monitoring or checkups are needed for the eyes while on Mayzent?

An ophthalmic evaluation (a specialized eye examination that includes the macula) should be obtained near the start of treatment. Official product information indicates that visual evaluations may be required if changes in vision are noticed during therapy.

Q: How long after starting Mayzent might a person begin to see the intended effects?

At the cellular level, Mayzent has a rapid onset of action, trapping immune cells in the lymphoid organs and causing a reduction in circulating lymphocytes within the first hours of treatment. The time until a person notices changes related to the course of their chronic condition can vary.

Q: What are the symptoms of potential liver problems related to Mayzent?

While increases in liver enzymes are a common side effect, symptoms suggestive of a serious liver problem may include unexplained nausea, vomiting, or stomach pain. Other possible signs include fatigue, dark urine, loss of appetite, or the yellowing of the skin or eyes, known as jaundice.

Q: What are the long-term safety concerns that have been studied for Mayzent?

Official information indicates that long-term exposure to Mayzent has been associated with an increased risk of skin malignancies (skin cancers). Additionally, its effects on the immune system are linked to an increased risk of serious infections.

Q: Are there any major risks if Mayzent treatment is suddenly stopped?

Official prescribing information indicates that treatment is typically withheld should a serious infection, such as Progressive Multifocal Leukoencephalopathy (PML), be suspected or diagnosed. After stopping the drug, the levels of trapped immune cells (lymphocyte counts) generally return to the normal range within approximately a week.

Q: Are there any known interactions between Mayzent and common over-the-counter pain relievers?

Caution is required when combining Mayzent with any drug that decreases heart rate due to the potential for additive effects on heart rhythm. The drug’s metabolism by specific enzymes means that interactions with other medicines, including over-the-counter products, are a possibility that is routinely considered in the prescribing process.

Q: How long does the drug stay in the body after a person stops taking Mayzent?

Mayzent has an apparent elimination half-life of approximately 30 hours. Studies indicate that it takes approximately 10 days for the drug to be completely eliminated from the body following the last dose.

Q: Can Mayzent be used by people with a prior history of the Herpes Zoster virus (shingles)?

Patients should be tested for antibodies to the varicella zoster virus (VZV), which causes shingles, before starting Mayzent. For individuals who test negative for antibodies, official guidelines describe that vaccination is typically considered before commencing treatment.

Q: What is the general information regarding breastfeeding while taking Mayzent?

Based on non-clinical data, Mayzent is considered potentially toxic to a breastfed infant, even if it is unlikely to reach breastmilk in large amounts. Official prescribing information notes the lack of specific data regarding use while breastfeeding.

Q: Does Mayzent cause a drop in white blood cell count?

Yes, Mayzent causes a dose-dependent reduction in the peripheral lymphocyte count, which is a type of white blood cell. This occurs because the drug works by temporarily trapping these specific immune cells within the lymphoid organs.

Q: Does Mayzent interact with any common anti-depressant or anxiety medications?

Mayzent is metabolized by specific enzymes. Interactions may occur with other medicines, including certain mental health drugs, that are known to moderately or strongly inhibit or induce these enzymes. Additionally, a potential interaction exists with drugs that may decrease heart rate.

Q: Are there specific symptoms that may indicate a serious side effect, such as PML, while on Mayzent?

Symptoms of serious conditions like Progressive Multifocal Leukoencephalopathy (PML) may include the new or worsening onset of clumsiness, balance problems, or weakness on one side of the body. Other reported signs include changes in thinking, memory, or vision.

Q: What is the purpose of the dose titration or 'starter pack' when beginning Mayzent treatment?

The mandatory titration period, or starter pack, is designed to gradually increase the drug dose. This gradual approach is used because the most significant transient effects on heart rate and conduction are seen during the initial dosing phase.

Q: Do patients need to limit sun exposure while taking Mayzent?

Mayzent use is associated with an increased risk of skin malignancies (skin cancers). Regulatory labeling indicates that due to the associated risk, skin examinations and appropriate protective measures are points of consideration during treatment.

Q: Does Mayzent interact with herbal supplements or vitamins?

Mayzent is primarily metabolized by specific liver enzymes. Herbal supplements or vitamins that are known to be moderate or strong inhibitors or inducers of these enzymes could potentially affect how the body handles the drug.

Q: What type of specialist typically manages Mayzent treatment?

Mayzent is a specialized medication used to treat multiple sclerosis, and its use is typically managed by a neurologist or another specialist with experience treating this specific neurological condition.

Q: Does Mayzent have any known major interactions with grapefruit or grapefruit juice?

Yes, official information indicates that the consumption of grapefruit juice can increase the body's exposure to Mayzent. This is because grapefruit juice affects the specific enzymes responsible for the drug’s breakdown and elimination.

Q: How often are blood tests required after starting Mayzent to monitor safety?

Official information states that blood tests are needed to check the liver and white blood cell count (Complete Blood Count) before starting treatment. Periodic monitoring of these values is generally recommended by official labeling during the course of treatment.

How to Store and Dispose of Mayzent (Siponimod)

Mayzent tablets must be stored according to specific regulatory guidelines to maintain stability.

Storage Requirements

Condition	Requirement
Unopened	Store in the refrigerator (between 2°C and 8°C or 36°F and 46°F). Do not freeze.
Opened (1 mg and 2 mg)	Store at controlled room temperature (below 30°C) for up to 3 months. Do not refrigerate after opening.
Protection	Keep in the original container/package away from light and moisture.
Child Safety	Keep this medication and all others out of reach of children and pets.

Disposal Instructions

When the product is expired or no longer needed, it must be properly discarded. Do not flush Mayzent down the toilet or pour it into a drain unless specifically instructed by a healthcare professional or regulatory body. Consult a pharmacist or local waste disposal company for guidance on appropriate disposal methods.